Traws Pharma Inc (TRAW)

$1.88 +0.25 (15.34%)
Market Cap 16.56M
Revenue (ttm) 2.79M
Net Income (ttm) 9.17M
EPS (ttm) N/A
PE Ratio 1.85
Forward PE N/A
Profit Margin 328.67%
Debt to Equity Ratio 0.00
Volume 1,936,400
Avg Vol 2,600,320
Day's Range N/A - N/A
Shares Out 10.16M
Stochastic %K 23%
Beta 1.47
Analysts Strong Sell
Price Target $5.50

Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 759 3680
Fax: 267 759 3681
Address:
12 Penns Trail, Newtown, United States
topstockalerts
topstockalerts May. 16 at 1:22 AM
$TRAW the move looks more deliberate than random.
0 · Reply
StockScanners
StockScanners May. 15 at 11:42 PM
$TRAW keep watch if this holds above 1.79
0 · Reply
jacksparo
jacksparo May. 15 at 10:10 PM
$TRAW Last night email Moved almost 20% today!
1 · Reply
CoffeeRocks
CoffeeRocks May. 15 at 8:58 PM
$TRAW next $NVAX $TNON $DRUG Lots of upside here
0 · Reply
dogood
dogood May. 15 at 8:46 PM
$VRAX look at this $TRAW goifn to break $2
0 · Reply
luminouslumens
luminouslumens May. 15 at 8:25 PM
$VRAX $TRAW Both at HOD, hantavirus news over the weekend? 🧐
0 · Reply
007Agent
007Agent May. 15 at 8:06 PM
$TRAW Hold MF, it is bulls turne.
0 · Reply
Rounderssss4
Rounderssss4 May. 15 at 7:26 PM
$TRAW let's pop this cherry
0 · Reply
007Agent
007Agent May. 15 at 4:26 PM
$TRAW Good and flat ER , I am holding next 3 months
0 · Reply
Merlintrader
Merlintrader May. 15 at 2:58 PM
$TRAW Viral Threats, Liver Fibrosis and Muscle Regeneration: $TRAW, $GALT and $MSLE Add Another Layer to the May 15 Biotech Tape https://www.merlintrader.com/viral-threats-may2026-update/
0 · Reply
Latest News on TRAW
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 18 hours ago

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

Traws Pharma files to sell 35.9M shares of common stock for holders

2026-05-08T22:46:20.000Z - 7 days ago

Traws Pharma files to sell 35.9M shares of common stock for holders

There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.

May 8, 2026, 1:43 PM EDT - 7 days ago

There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some.

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

May 8, 2026, 7:30 AM EDT - 7 days ago

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

Traws Pharma Earnings Call Transcript: Q4 2025

Apr 15, 2026, 4:30 PM EDT - 4 weeks ago

Traws Pharma Earnings Call Transcript: Q4 2025

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Apr 15, 2026, 4:01 PM EDT - 4 weeks ago

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Traws Pharma completes clinical analysis of Phase 2 study of ratutrelvir

2026-02-19T12:43:19.000Z - 3 months ago

Traws Pharma completes clinical analysis of Phase 2 study of ratutrelvir

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Feb 19, 2026, 7:30 AM EST - 3 months ago

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Traws Pharma initiated with a Buy at Ladenburg

2026-01-30T12:20:23.000Z - 3 months ago

Traws Pharma initiated with a Buy at Ladenburg

Traws Pharma completes enrollment in Phase 2 study of ratutrelvir

2026-01-26T13:35:09.000Z - 3 months ago

Traws Pharma completes enrollment in Phase 2 study of ratutrelvir

Traws Pharma files tivoxavir marboxil IND application with U.S. FDA

2026-01-13T12:05:30.000Z - 4 months ago

Traws Pharma files tivoxavir marboxil IND application with U.S. FDA

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

Jan 13, 2026, 7:00 AM EST - 4 months ago

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

Traws Pharma reports ‘positive’ interim data with ratutrelvir vs. paxlovid

2025-12-17T11:11:13.000Z - 5 months ago

Traws Pharma reports ‘positive’ interim data with ratutrelvir vs. paxlovid

Traws Pharma initiated with a Buy at H.C. Wainwright

2025-12-03T11:10:09.000Z - 5 months ago

Traws Pharma initiated with a Buy at H.C. Wainwright

Traws Pharma reports Q3 EPS (34c) vs ($1.49) last year

2025-11-13T12:05:59.000Z - 6 months ago

Traws Pharma reports Q3 EPS (34c) vs ($1.49) last year

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Oct 30, 2025, 12:00 PM EDT - 7 months ago

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Oct 22, 2025, 6:40 PM EDT - 7 months ago

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

Traws Pharma doses first patient with ratutrelvir in Phase 2 COVID studies

2025-10-14T11:10:48.000Z - 7 months ago

Traws Pharma doses first patient with ratutrelvir in Phase 2 COVID studies

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Oct 14, 2025, 7:00 AM EDT - 7 months ago

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

Traws Pharma appoints John Leaman as independent director

2025-10-06T11:37:17.000Z - 7 months ago

Traws Pharma appoints John Leaman as independent director

Traws Pharma receives approval to proceed with Phase 2 COVID studies

2025-08-18T11:05:38.000Z - 9 months ago

Traws Pharma receives approval to proceed with Phase 2 COVID studies

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Aug 18, 2025, 7:00 AM EDT - 9 months ago

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

Traws Pharma Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 9 months ago

Traws Pharma Earnings Call Transcript: Q2 2025

Traws Pharma reports Q2 EPS (11c) vs. ($20.52) last year

2025-08-14T11:16:52.000Z - 9 months ago

Traws Pharma reports Q2 EPS (11c) vs. ($20.52) last year

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Aug 14, 2025, 7:00 AM EDT - 9 months ago

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Aug 8, 2025, 7:00 AM EDT - 10 months ago

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Traws Pharma announced multiple regulatory submissions

2025-06-30T10:44:40.000Z - 11 months ago

Traws Pharma announced multiple regulatory submissions

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Jun 30, 2025, 6:30 AM EDT - 11 months ago

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

Traws Pharma Stock (TRAW) Surges 55% on Positive Cancer Data

2025-06-03T13:48:21.000Z - 1 year ago

Traws Pharma Stock (TRAW) Surges 55% on Positive Cancer Data

Traws Pharma publishes key efficacy data for rigosertib

2025-06-03T11:05:56.000Z - 1 year ago

Traws Pharma publishes key efficacy data for rigosertib

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

Traws Pharma announces receipt of FDA guidance on tivoxavir marboxil

2025-05-27T12:10:16.000Z - 1 year ago

Traws Pharma announces receipt of FDA guidance on tivoxavir marboxil

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025, 8:00 AM EDT - 1 year ago

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

Traws Pharma reports Q1 EPS $2.09) vs ($5.92) last year

2025-05-15T11:14:04.000Z - 1 year ago

Traws Pharma reports Q1 EPS $2.09) vs ($5.92) last year

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Traws Pharma Earnings Call Transcript: Q4 2024

Mar 31, 2025, 10:00 AM EDT - 1 year ago

Traws Pharma Earnings Call Transcript: Q4 2024

Traws Pharma reports FY24 EPS ($35.21)

2025-03-31T13:11:18.000Z - 1 year ago

Traws Pharma reports FY24 EPS ($35.21)

Traws Pharma CEO Werner Cautreels retires, Iain Dukes named interim CEO

2025-03-28T20:35:29.000Z - 1 year ago

Traws Pharma CEO Werner Cautreels retires, Iain Dukes named interim CEO

Traws Pharma Announces Management Updates

Mar 28, 2025, 4:30 PM EDT - 1 year ago

Traws Pharma Announces Management Updates

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Mar 26, 2025, 7:30 AM EDT - 1 year ago

Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Mar 21, 2025, 7:00 AM EDT - 1 year ago

Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Mar 3, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Feb 28, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Jan 23, 2025, 7:00 AM EST - 1 year ago

Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Jan 10, 2025, 5:55 PM EST - 1 year ago

Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Dec 30, 2024, 8:00 AM EST - 1 year ago

Traws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to Approval

Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 12:00 PM EST - 1 year ago

Traws Pharma stock soars 200% on encouraging bird flu drug data

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Dec 23, 2024, 7:00 AM EST - 1 year ago

Traws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Nov 14, 2024, 4:30 PM EST - 1 year ago

Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Sep 30, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 20, 2024, 7:30 AM EDT - 1 year ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Sep 17, 2024, 4:05 PM EDT - 1 year ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Traws Pharma Earnings Call Transcript: Q2 2024

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Traws Pharma Earnings Call Transcript: Q2 2024

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Aug 15, 2024, 7:00 AM EDT - 1 year ago

Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET

Traws Pharma Transcript: M&A Announcement

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Traws Pharma Transcript: M&A Announcement

Traws Pharma Announces New Employee Inducement Grants

Apr 2, 2024, 7:15 AM EDT - 2 years ago

Traws Pharma Announces New Employee Inducement Grants

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Mar 8, 2024, 8:00 AM EST - 2 years ago

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Dec 8, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Nov 28, 2023, 8:00 AM EST - 2 years ago

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Traws Pharma Earnings Call Transcript: Q3 2023

Nov 14, 2023, 4:30 PM EST - 2 years ago

Traws Pharma Earnings Call Transcript: Q3 2023

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Nov 14, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Nov 7, 2023, 4:05 PM EST - 2 years ago

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Nov 2, 2023, 10:37 AM EDT - 2 years ago

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Onconova Expands Leadership Team with Two Key Appointments

Oct 24, 2023, 8:00 AM EDT - 2 years ago

Onconova Expands Leadership Team with Two Key Appointments

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Traws Pharma Earnings Call Transcript: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 3 years ago

Traws Pharma Earnings Call Transcript: Q2 2023

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Jun 14, 2023, 8:00 AM EDT - 3 years ago

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Jun 5, 2023, 8:00 AM EDT - 3 years ago

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Traws Pharma Earnings Call Transcript: Q1 2023

May 15, 2023, 4:30 PM EDT - 3 years ago

Traws Pharma Earnings Call Transcript: Q1 2023

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 15, 2023, 4:18 PM EDT - 3 years ago

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

May 12, 2023, 8:00 AM EDT - 3 years ago

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

May 4, 2023, 4:05 PM EDT - 3 years ago

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

topstockalerts
topstockalerts May. 16 at 1:22 AM
$TRAW the move looks more deliberate than random.
0 · Reply
StockScanners
StockScanners May. 15 at 11:42 PM
$TRAW keep watch if this holds above 1.79
0 · Reply
jacksparo
jacksparo May. 15 at 10:10 PM
$TRAW Last night email Moved almost 20% today!
1 · Reply
CoffeeRocks
CoffeeRocks May. 15 at 8:58 PM
$TRAW next $NVAX $TNON $DRUG Lots of upside here
0 · Reply
dogood
dogood May. 15 at 8:46 PM
$VRAX look at this $TRAW goifn to break $2
0 · Reply
luminouslumens
luminouslumens May. 15 at 8:25 PM
$VRAX $TRAW Both at HOD, hantavirus news over the weekend? 🧐
0 · Reply
007Agent
007Agent May. 15 at 8:06 PM
$TRAW Hold MF, it is bulls turne.
0 · Reply
Rounderssss4
Rounderssss4 May. 15 at 7:26 PM
$TRAW let's pop this cherry
0 · Reply
007Agent
007Agent May. 15 at 4:26 PM
$TRAW Good and flat ER , I am holding next 3 months
0 · Reply
Merlintrader
Merlintrader May. 15 at 2:58 PM
$TRAW Viral Threats, Liver Fibrosis and Muscle Regeneration: $TRAW, $GALT and $MSLE Add Another Layer to the May 15 Biotech Tape https://www.merlintrader.com/viral-threats-may2026-update/
0 · Reply
Trader9955
Trader9955 May. 15 at 2:38 PM
$TRAW I’m in 💰 12 month PT $5.50
0 · Reply
trademx71
trademx71 May. 15 at 2:35 PM
$TRAW These guys are not nervous putting much more money than me, it coult mean I should be less nervous than them.
0 · Reply
CometaMan
CometaMan May. 15 at 1:27 PM
$TRAW I’m watching closely, will jump back in when it hits the $1.30s
0 · Reply
TrixMixTick
TrixMixTick May. 15 at 1:18 PM
$TRAW
0 · Reply
SMM36
SMM36 May. 15 at 1:14 PM
$TRAW Warren Buffett's core strategy remains focused on identifying companies selling for less than their intrinsic value, often summarizing this with: "Price is what you pay, value is what you get"…. load up
0 · Reply
Jbjb90
Jbjb90 May. 15 at 11:54 AM
$TRAW
0 · Reply
Jbjb90
Jbjb90 May. 15 at 11:34 AM
$TRAW https://www.stocktitan.net/news/TRAW/traws-pharma-provides-business-highlights-and-reports-q1-2026-pjtx76wex387.html
0 · Reply
focafoca99
focafoca99 May. 15 at 11:20 AM
$TRAW just got its Q1 2026 earnings release, reporting results for the quarter ended March 31, 2026. https://www.rapidticker.com/news/traw-sec-filing-cb6893
0 · Reply
focafoca99
focafoca99 May. 15 at 11:10 AM
$TRAW updates its business highlights, reporting a $60M private financing and Q1 2026 results as it funds operations into 2027. https://www.rapidticker.com/news/traw-traws-pharma-provides-business-highlights-efdbb0
0 · Reply
SexyStockSlayer
SexyStockSlayer May. 14 at 11:39 PM
$TRAW wow
1 · Reply
007Agent
007Agent May. 14 at 7:59 PM
$TRAW This stock requires smart retail investors, it will pop up 20X,Hold
0 · Reply
Sektorrr
Sektorrr May. 14 at 7:39 PM
$TRAW joke volume
0 · Reply